G. Odom

发表

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

R. David Hawkins, John K. Hall, R. D. Hawkins, 2017, Nature Communications.

Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor.

J. Shellito, J. Kolls, S. Nelson, 1997, American journal of respiratory cell and molecular biology.

Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy

G. Mahairas, M. Regnier, J. Chamberlain, 2016, JACC. Basic to translational science.

Animal models of muscular dystrophy.

John K. Hall, J. Seto, J. Chamberlain, 2012, Progress in molecular biology and translational science.

Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model

J. Chamberlain, Jeovanna Lowe, J. Rafael-Fortney, 2021, JCI insight.

Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6.

James M. Allen, J. Chamberlain, P. Gregorevic, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Preclinical Studies for Gene Therapy of Duchenne Muscular Dystrophy

J. Chamberlain, P. Gregorevic, B. Schultz, 2010, Journal of child neurology.

Adeno-associated viral vectors do not efficiently target muscle satellite cells

John K. Hall, Z. Yablonka-Reuveni, J. Chamberlain, 2014, Molecular therapy. Methods & clinical development.

Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors.

J. Shellito, J. Kolls, M. Gerber, 1996, Human gene therapy.

Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

J. Seto, J. Chamberlain, Lindsey A. Muir, 2012, Current gene therapy.

Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice

K. Davies, L. Moir, D. Golebiowski, 2018, Molecular therapy. Methods & clinical development.

Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

J. Straková, D. Townsend, G. Odom, 2014, Journal of molecular and cellular cardiology.

Extracorporeal Delivery of rAAV with Metabolic Exchange and Oxygenation

J. Chamberlain, Suhail Ahmad, E. Finn, 2013, Scientific Reports.

Validation of ultrasonography for non‐invasive assessment of diaphragm function in muscular dystrophy

M. Kim, N. Whitehead, S. Froehner, 2016, The Journal of physiology.

Recombinant adeno‐associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia

G. Garden, J. Chamberlain, B. Sopher, 2016, Journal of neurochemistry.

Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

J. Chamberlain, P. Gregorevic, G. Odom, 2007, Biochimica et biophysica acta.

Muscle Structure Influences Utrophin Expression in mdx Mice

J. Chamberlain, R. Bloch, G. Odom, 2014, PLoS genetics.

rAAV6‐Microdystrophin Rescues Aberrant Golgi Complex Organization in mdx Skeletal Muscles

J. Chamberlain, J. Percival, S. Froehner, 2007, Traffic.

Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

John K. Hall, J. Seto, J. Chamberlain, 2016, Human molecular genetics.

Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate

John K. Hall, M. Regnier, J. Chamberlain, 2019, JACC. Basic to translational science.

Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16–17

M. Kim, J. Chamberlain, S. Froehner, 2018, Human molecular genetics.

Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.

J. Chamberlain, P. Gregorevic, E. Finn, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

D. Goodlett, S. Shaffer, J. Chamberlain, 2014, Human molecular genetics.

Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects

J. Chamberlain, G. Odom, G. Banks, 2020, PLoS genetics.

Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene.

J. Lancaster, J. Shellito, J. Kolls, 1997, The American journal of physiology.

AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.

G. Mahairas, M. Regnier, C. Murry, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle

J. Chamberlain, G. Gowda, G. Odom, 2023, Research Square.

Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model

J. Chamberlain, Jeovanna Lowe, J. Rafael-Fortney, 2023, Molecular therapy. Methods & clinical development.

Cell based dATP delivery as a therapy for chronic heart failure

R. Tian, D. Raftery, C. Murry, 2023, bioRxiv.

Human retroelements may introduce intragenic polyadenylation signals

P. Deininger, G. Odom, A. M. Roy-Engel, 2005, Cytogenetic and Genome Research.

Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.

E. Alexander, S. Green, P. Burger, 1989, International journal of radiation oncology, biology, physics.

Predicting mammalian SINE subfamily activity from A-tail length.

Jennifer L. Robichaux, P. Deininger, G. Odom, 2004, Molecular biology and evolution.

Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

D. Goodlett, S. Shaffer, J. Chamberlain, 2014, Human molecular genetics.

Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

John K. Hall, R. D. Hawkins, J. Chamberlain, 2017, Nature Communications.

AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.

G. Mahairas, M. Regnier, C. Murry, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.